Milestone Scientific Inc (MLSS)

Form PRE 14A - Other preliminary proxy statements

Form S-3 - Registration statement under Securities Act of 1933

Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures

ROSELAND, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading...

Milestone Scientific Reports Financial Results for First Quarter 2026

Operating Loss Reduced As Company Advances Toward Profitability Reaffirms Outlook for Double-Digit Revenue...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Milestone Scientific Schedules First Quarter 2026 Financial Results and Business Update Conference Call

ROSELAND, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer...

Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption

ROSELAND, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer...

Form 8-K - Current report

Form 8-K - Current report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 8-K - Current report

Milestone Scientific Inc. Completes $2.15 Million Private Placement

ROSELAND, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading...

Form 8-K - Current report

Milestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025

Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]